top of page
  • Active, not recruiting

NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)

Updated: Sep 25, 2022



IMROZ study sanofi

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Primary Objective:

To demonstrate the benefit of isatuximab (I) in combination with bortezomib (V), lenalidomide (R) and dexamethasone (d) in the prolongation of progression free survival (PFS) as compared with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant.

Secondary Objectives:

To evaluate in both randomized arms: very good partial response (VGPR) or better rate as defined by the International Myeloma Working Group (IMWG) criteria, minimal residual disease (MRD) negativity rate in patients with complete response (CR) or VGPR, CR rate per IMWG criteria, time to progression (TTP) and overall by MRD status, PFS in MRD negative patients, duration of response (DOR) and overall by MRD status, time to first response (TT1R), time to best response (TTBR), PFS on next line of therapy (PFS2), overall survival (OS), overall response rate (ORR) per IMWG criteria (including crossover arm), safety (including crossover arm), and to assess disease-specific and generic health-related quality of life (HRQL)

To determine the pharmacokinetic (PK) profile of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (excluding crossover arm)

To evaluate the immunogenicity of isatuximab in patients receiving isatuximab (including crossover arm)


Multiple locations

International Study Identifier: NCT03319667

Official Title: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant

First Posted : October 24, 2017

Click here for details on


Drug: Isatuximab SAR650984

Drug: Bortezomib

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Acetaminophen (paracetamol) or equivalent

Drug: Ranitidine or equivalent

Drug: Diphenhydramine or equivalent



United States, Florida

United States, Missouri

United States, Tennessee

United States, Texas


Australia, New South Wales

Australia, Queensland

Australia, Victoria

Australia, Western Australia

New Zealand

















Russian Federation




NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM

NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM

NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM

NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab

NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT

NCT02874742: Phase 2 (GRIFFIN) - Dara-VRd Vs VRd - Daratumumab, Len., Bortezomib & Dex in NDMM

NCT04268498: Phase2 (ADVANCE) Dara-KRd - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma

NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D

NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma

NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma

NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM

NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients


NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT

NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients


NCT04923893: Phase 3 (CARTITUDE-5) VRd --> Cilta-cel Vs VRd --> Rd - NDMM- (No ASCT planned)

NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM


NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM


Posts Archive
bottom of page